Puma Biotechnology Q3 net loss narrows to $0.4M; raises FY 2022 NERLYNX revenue guidance

PUMA BIOTECHNOLOGY, INC.

2022-Q3 EPS reported $0.13 revenue$162,356,000

Q3 product revenue $54.3M, up 25% YoY from $43.4M; net loss $0.4M ($0.01/share) vs $44.7M loss in Q3 2021.
Non-GAAP adjusted net income $2.5M ($0.05/share) vs adjusted loss of $40.4M a year ago.
Raises FY 2022 product revenue guidance to $194-$196M from prior $180-$190M; net income guidance $7-$9M.
In-licensed alisertib (aurora kinase A inhibitor) from Takeda for $7M upfront; plans initial trials in HR+ breast cancer and small cell lung cancer.
Cash and marketable securities $78.0M at Sep 30, 2022; operating cash flow $17.3M in Q3.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

PUMA BIOTECHNOLOGY, INC. reported third quarter ended September 30, 2022 results: revenue $54.3 million, net income Net loss of $0.4 million, or $0.01 per share, EPS $0.01 per share. Guidance raised.

Period: third quarter ended September 30, 2022
Revenue: $54.3 million
Net income: Net loss of $0.4 million, or $0.01 per share
EPS: $0.01 per share
Guidance: raised
Result: reported results

Exact text from the filing

quarter of 2021. Product revenue, net consists entirely of sales revenue from NERLYNX®, Puma’s first commercial product. Product revenue, net in the third quarter of 2022 was $54.3 million, compared to $43.4 million in the third quarter of 2021. Product revenue, net in the first nine months of 2022 was $146.3 million, compared to $138.1 million in the first nine

View on SEC.gov

Browse all earnings releases →

PUMA BIOTECHNOLOGY, INC. filing history →

Source: SEC EDGAR

accession 0001437749-22-025761

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.